Table 1 In vitro fertilisation experiments.

From: Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene

Genotype

Treatment

Oocyte co l lection

Fertilisation and embryo development

Mouse ID

# Total

# Degenerated

# 2-cell embryos

% Fertilisation

# Blastocysts

% Blastocysts

Brip1+/-

Carboplatin + Paclitaxel

F41

11

0

2

18.2

0

0.0

F4

0

0

0

0.0

0

0.0

F1

14

0

4

28.6

2

50.0

F3

1

0

0

0.0

0

0.0

F14

14

1

6

46.2

2

33.3

Summary

40a

1

12

30.8 b

4

33.3b

Control

F4

35

0

18

51.4

10

55.6

F43

43

1

20

47.6

11

55.0

F4

26

3

12

52.2

8

66.7

F1

28

5

16

69.6

10

62.5

F3

26

4

18

81.8

8

44.4

Summary

158

13

84

57.9

47

56.0

Brip1+/+

Carboplatin + Paclitaxel

F3

4

0

0

0.0

0

0.0

F10

0

0

0

0.0

0

0.0

F10

16

1

2

13.3

0

0.0

F31

21

6

1

6.7

0

0.0

F33

12

0

8

66.7

4

50.0

Summary

53 b

7

11

23.9a

4

36.4b

Control

F44

30

5

16

64.0

8

50.0

F10

28

4

14

58.3

8

57.1

F1

17

2

10

66.7

6

60.0

F41

47

1

28

60.9

18

64.3

F1

30

5

14

56.0

6

42.9

Summary

152

17

82

60.7

46

56.1

  1. Oocyte recovery, fertilisation rate and embryo developmental competence in Brip1+/− and Brip1+/+ mice treated with the combination of carboplatin and paclitaxel or with NaCl 0.9% (control group), three weeks after the completion of the treatment. n = 5/treatment/genotype.
  2. ap < 0.01, bp < 0.05.